Ann: ACW XanaCIDD depression trial results expected early August, page-53

Good post.

What's probably of more interest than the rise IN SAVA - NASDAQ is the Market cap of Cassava, which is fast approaching $1bn AUD. Exciting for ACW - ASX holders given Actinogen's Xanamem has the potential to treat close to a dozen neurological disorders including Alzhiemer's.

There is often a disparity between the Nasdaq and ASX biotechs but this does highlight what Actinogen Steven Gourlay has been stating for some time. If results in Actinogen's two current Phase 2 trial for both depression and AD replicate earlier clinical trials and continue to trend positively, as suggested by CMO Dana hilt, a significant rerate is on the cards ACW.


DYOR